HK1248588A1 - 用於癌症治療中的天花疫苗 - Google Patents

用於癌症治療中的天花疫苗

Info

Publication number
HK1248588A1
HK1248588A1 HK18108467.7A HK18108467A HK1248588A1 HK 1248588 A1 HK1248588 A1 HK 1248588A1 HK 18108467 A HK18108467 A HK 18108467A HK 1248588 A1 HK1248588 A1 HK 1248588A1
Authority
HK
Hong Kong
Prior art keywords
cancer treatment
smallpox vaccine
smallpox
vaccine
cancer
Prior art date
Application number
HK18108467.7A
Other languages
English (en)
Inventor
Aladar Szalay
Boris Minev
Original Assignee
Calidi Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calidi Biotherapeutics Inc filed Critical Calidi Biotherapeutics Inc
Publication of HK1248588A1 publication Critical patent/HK1248588A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18108467.7A 2015-08-11 2018-06-29 用於癌症治療中的天花疫苗 HK1248588A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562203835P 2015-08-11 2015-08-11
US201562216292P 2015-09-09 2015-09-09
US201662317226P 2016-04-01 2016-04-01
PCT/US2016/046647 WO2017027757A2 (en) 2015-08-11 2016-08-11 Smallpox vaccine for cancer treatment

Publications (1)

Publication Number Publication Date
HK1248588A1 true HK1248588A1 (zh) 2018-10-19

Family

ID=56787706

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18108467.7A HK1248588A1 (zh) 2015-08-11 2018-06-29 用於癌症治療中的天花疫苗

Country Status (10)

Country Link
US (4) US10105436B2 (zh)
EP (1) EP3334456A2 (zh)
JP (1) JP6788663B2 (zh)
KR (1) KR102201147B1 (zh)
CN (2) CN108135996B (zh)
CA (1) CA3004891C (zh)
EA (1) EA201800148A1 (zh)
HK (1) HK1248588A1 (zh)
MX (1) MX2018001755A (zh)
WO (1) WO2017027757A2 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017005325A (es) 2014-10-24 2018-01-11 Stemimmune Incorporated Enfoque de inmunoterapias de combinación para el tratamiento del cancer.
EA201800148A1 (ru) * 2015-08-11 2019-01-31 Калиди Биотерапьютикс, Инк. Оспенная вакцина для лечения рака
TW201819400A (zh) 2016-11-02 2018-06-01 大衛 伊凡斯 合成之嵌合痘病毒
AU2018316166A1 (en) 2017-08-07 2020-02-06 The Regents Of The University Of California Platform for generating safe cell therapeutics
KR20200111168A (ko) 2017-11-24 2020-09-28 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 암 치료를 위한 방법 및 조성물
TW202014200A (zh) * 2018-05-02 2020-04-16 賽斯 雷德曼 包含合成嵌合牛痘病毒之幹細胞及其使用方法
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
JP7329593B2 (ja) 2018-11-06 2023-08-18 カリディ・バイオセラピューティクス・インコーポレイテッド 細胞媒介性腫瘍溶解性ウイルス治療のための増強された系
CA3142124A1 (en) * 2019-05-30 2020-12-03 Immunolux International Corp. Use of poxvirus with autologous induced pluripotent stem cells for vaccination and disease therapy
US11110165B2 (en) 2019-10-10 2021-09-07 Ricardo Rosales Ledezma Therapeutic vaccine for the treatment of papillomavirus lesions
CN116056716A (zh) * 2020-05-15 2023-05-02 首尔大学校产学协力团 利用从脂肪组织分离出来的基质血管组分的树突状细胞的激活功能的免疫反应增强用组合物
WO2022086300A1 (ko) * 2020-10-23 2022-04-28 에스케이바이오사이언스 주식회사 외래 항원을 코딩하는 유전물질을 포함하는, 타겟 조직의 크기 또는 부피 축소용 백신 조성물 또는 키트
WO2023204693A1 (ko) * 2022-04-22 2023-10-26 에스케이바이오사이언스 주식회사 타겟 조직의 크기 또는 부피 축소용 조성물 또는 이를 포함하는 키트

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020010144A1 (en) 1994-04-29 2002-01-24 Robert Sobol Enhancing the sensitivity of tumor cells to therapies
CA2720361A1 (en) 1999-11-12 2001-05-25 Oncolytics Biotech, Inc. Viruses for the treatment of cellular proliferative disorders
DE602004018927D1 (de) * 2003-06-18 2009-02-26 Genelux Corp Modifizierte rekombinante vacciniaviren, verwendungen davon
NZ581958A (en) 2004-11-12 2011-01-28 Bayer Schering Pharma Ag Recombinant newcastle disease virus comprising a transgene encoding a prodrug-converting enzyme or protease for use in the treatment of cancer
CA2656379A1 (en) 2006-06-21 2007-12-27 Apogenix Gmbh Differential cytokine expression in human cancer
WO2008009115A1 (en) 2006-07-18 2008-01-24 Ottawa Health Research Institute Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses
EP2415783B1 (en) 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
US20100183542A1 (en) 2006-10-24 2010-07-22 University Of South Alabama Synergism Between Activated Immune Cells and Conventional Cancer Therapies
US8445275B2 (en) 2007-04-27 2013-05-21 Bavarian Nordic A/S Induction of dendritic cell development with macrophage-colony stimulating factor (M-CSF)
JP2010533718A (ja) 2007-07-18 2010-10-28 ジェネラックス・コーポレイション 腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
US20120052003A9 (en) 2008-05-16 2012-03-01 Szalay Aladar A Microorganisms for preventing and treating neoplasms accompanying cellular therapy
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
EP2352526A1 (en) 2008-09-19 2011-08-10 Protox Therapeutics Inc. Treating cancer stem cells using targeted cargo proteins
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
KR20120088542A (ko) 2009-04-13 2012-08-08 아프세스 게엠베하 & 씨오. 카게 종양 치료를 위한 조작된 중간엽 줄기세포 및 이를 사용하는 방법
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
US20110027239A1 (en) 2009-07-29 2011-02-03 Tissue Genesis, Inc. Adipose-derived stromal cells (asc) as delivery tool for treatment of cancer
JP5035737B2 (ja) 2009-12-07 2012-09-26 国立大学法人名古屋大学 脂肪組織由来間葉系幹細胞を含有する、前立腺癌治療用細胞製剤
US20140017787A1 (en) 2010-10-11 2014-01-16 Aline M. Betancourt Mesenchymal stem cells and related therapies
EP2632481A1 (en) 2010-10-25 2013-09-04 Regents Of The University Of Minnesota Therapeutic composition for treatment of glioblastoma
US8859256B2 (en) * 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
SG10201604654RA (en) 2012-01-25 2016-07-28 Dnatrix Inc Biomarkers and combination therapies using oncolytic virus and immunomodulation
KR20150038066A (ko) 2012-07-30 2015-04-08 알렉스 와 힌 영 종양 세포, 암세포파괴 바이러스 벡터 및 면역 체크포인트 조절인자를 갖는 암 백신 시스템
US10034939B2 (en) 2012-10-26 2018-07-31 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
WO2014160475A1 (en) 2013-03-13 2014-10-02 Aboody Karen S Tropic cell based virotherapy for the treatment of cancer
JP6596411B2 (ja) 2013-03-14 2019-10-23 アイカーン スクール オブ メディシン アット マウント サイナイ ニューカッスル病ウイルス及びその使用
US10350275B2 (en) 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
US20160303174A1 (en) 2013-12-11 2016-10-20 The General Hospital Corporation Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors
EP3169341B1 (en) 2014-07-16 2019-06-05 Transgene SA Oncolytic virus for expression of immune checkpoint modulators
MX2017005325A (es) 2014-10-24 2018-01-11 Stemimmune Incorporated Enfoque de inmunoterapias de combinación para el tratamiento del cancer.
WO2016149559A1 (en) 2015-03-18 2016-09-22 Aladar Szalay Virotherapy with an antibody combination
EA201800148A1 (ru) 2015-08-11 2019-01-31 Калиди Биотерапьютикс, Инк. Оспенная вакцина для лечения рака
WO2019236633A2 (en) 2018-06-04 2019-12-12 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
JP7329593B2 (ja) 2018-11-06 2023-08-18 カリディ・バイオセラピューティクス・インコーポレイテッド 細胞媒介性腫瘍溶解性ウイルス治療のための増強された系
JP2022534783A (ja) 2019-06-03 2022-08-03 イミュノルクス インターナショナル コーポレーション 疾患を処置するための天然痘ワクチン及び幹細胞

Also Published As

Publication number Publication date
MX2018001755A (es) 2018-08-01
US20170043010A1 (en) 2017-02-16
CA3004891A1 (en) 2017-02-16
US20180326048A1 (en) 2018-11-15
US10105436B2 (en) 2018-10-23
US12036278B2 (en) 2024-07-16
KR102201147B1 (ko) 2021-01-11
CN108135996B (zh) 2022-06-21
US20210046178A1 (en) 2021-02-18
CA3004891C (en) 2020-04-14
WO2017027757A3 (en) 2017-03-23
JP6788663B2 (ja) 2020-11-25
JP2018527344A (ja) 2018-09-20
WO2017027757A2 (en) 2017-02-16
KR20180042284A (ko) 2018-04-25
US20230173062A1 (en) 2023-06-08
CN108135996A (zh) 2018-06-08
EA201800148A1 (ru) 2019-01-31
US10857225B2 (en) 2020-12-08
EP3334456A2 (en) 2018-06-20
CN115212301A (zh) 2022-10-21
US11607450B2 (en) 2023-03-21

Similar Documents

Publication Publication Date Title
HK1248588A1 (zh) 用於癌症治療中的天花疫苗
HK1248137A1 (zh) 用於治療癌症的聚乙二醇化白細胞介素-10
IL254705A0 (en) Combination therapy for cancer
HK1252967A1 (zh) 治療性hpv18疫苗
IL251630A0 (en) Combined therapy for use in cancer treatment
HK1231561A1 (zh) 癌症治療
IL251903A0 (en) Epilimod for use in the treatment of colon cancer
IL262143A (en) Improvements in cancer treatment
IL255560B (en) Macropinocytosis in cancer
GB201409363D0 (en) Skin cancer treatment
SG10202001388YA (en) Use of ureidomustine (bo-1055) in cancer treatment
HK1251794A1 (zh) 癌症治療
GB201519734D0 (en) Cancer therapy
HK1254687A1 (zh) 用於癌症的聯合療法
IL260988A (en) ptps-based vaccines against cancer
GB201522433D0 (en) Cancer treatment
GB2578008B (en) 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment
HRP20210383T8 (hr) Kombinirana terapija za rak
GB2553684B (en) Ethynylxanthines, preparation and use for cancer treatment
EP3261673B8 (en) Combined vaccination/radioterapy for cancer treatment
GB201511609D0 (en) Cancer therapy
GB201511120D0 (en) Cancer therapy
GB201511121D0 (en) Cancer therapy
GB201506944D0 (en) Therapeutic treatment
GB201411884D0 (en) Cancer therapy